ArticleFrontiers in immunology2025
SWI/SNF complex alterations predict immunotherapy response in bladder cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bladder Cancer Biomarkers: Recent Advances in Early Detection, Treatment Prediction, and Prognosis.Oncology research · 2026Review
- Immunotherapy role in bladder cancer treatment: a review of literature.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors have revolutionized the treatment of urothelial bladder cancer (UBC), yet response remains limited to a subset of patients. The SWItch/sucrose non-fermentable (SWI/SNF) chromatin remodeling complex is recurrently altered across cancers, but its prevalence, functional impact, and predictive value in UBC remain unclear. This study aimed to comprehensively delineate the mutational spectrum of SWI/SNF genes in UBC and assess their utility as predictive biomarkers for response to immune checkpoint blockade. Methods: We analyzed tumor specimens from 49 patients in the Daping Cohort and integrated data from five independent public cohorts comprising 2,280 cases in total. Somatic alterations were identified using targeted or whole-exome sequencing, and transcriptomic profiles were obtained from RNA sequencing datasets. Survival outcomes were evaluated using Kaplan-Meier survival analysis and time-dependent ROC curves. Tumor immune landscape was characterized via xCell-based deconvolution and corroborated by multiplex immunofluorescence on institutional samples. Prognostic modeling was performed across 65 machine-learning configurations, encompassing survival SVM, CoxBoost, and stepwise Cox, with external validation in independent cohorts. Results: SWI/SNF alterations were present in 42.8% of UBCs, with the highest frequencies in Conclusions: SWI/SNF alterations define an immunotherapy-responsive stratification of UBC. The accompanying genotype-specific prognostic models provide a ready-to-test framework for guiding precision immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.